Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐Induced neutropenia

BACKGROUND: Sargramostim is a granulocyte‐macrophage–colony‐stimulating factor (GM‐CSF). Unlike filgrastim and pegfilgrastim, which are granulocyte–colony‐stimulating factors (G‐CSFs), sargramostim activates a broader range of myeloid lineage‐derived cells. Therefore, GM‐CSF might reduce infection r...

Ausführliche Beschreibung